EMA has published today a report highlighting the Agency’s support for micro, small and medium-sized enterprises (SMEs) which develop and market medicines for human or veterinary use in the European Union. The report covers the period from 2016 to 2020.

Since 2016, the success rate of marketing authorisation applications for human medicines submitted by SMEs has more than doubled. In 2016, 40% of medicines with an SME applicant received a positive opinion. In 2020, the number had increased to 89%. In 2020 alone, SMEs were behind 16 recommendations for approval of a new medicine, which accounted for almost 20% of all medicines for human use recommended for approval by EMA last year. Half of them targeted rare diseases.

In the veterinary area, 14 medicines received a positive opinion by the Agency in the last five years. Almost half of these had received scientific advice from the Agency. Six out of the 14 were veterinary medicines for minor use / minor species (MUMS).

The report features key facts and figures of companies that are registered as SMEs with EMA. SMEs are a major driver of innovation in the pharmaceutical industry and the Agency provides them with access to a number of incentives, including regulatory assistance from a dedicated SME Office and reduced fees for certain procedures.

15 years of support to SMEs

The publication of the report marks the 15-year anniversary of the adoption of the SME Regulation that promotes innovation and the development of new medicines in Europe. Since the creation of the SME Office in 2005, more than 130 medicines developed by SMEs have been approved following an EMA recommendation and contribute to public and animal health.

How useful do you find this page?